NanJing Pharmaceutical Company Limited operates primarily in pharmaceutical manufacturing, focusing on chemical generic drugs including pharmaceutical active pharmaceutical ingredients (APIs), biological products, and plasma products. Its product portfolio covers a wide range of therapeutic segments such as antidiabetic, cardiovascular, central nervous system, antifungal, neuromuscular blockade reversal, and antiepileptics. Key pharmaceutical products include Apremilast, Indacaterol, Sugammadex Sodium, Posaconazole, Amphotericin B, Brivaracetam, Liraglutide, Empagliflozin, Dapagliflozin, and Canagliflozin. The company also produces human fibrinogen derived from purified plasma. NanJing Pharmaceutical exports its products to nearly 60 countries and integrates its business across four major sectors: pharmaceutical international trading, technology transfer, regulatory affairs consultation, and supply chain and sales channel integration.
The company emphasizes high-quality standards with several branded APIs recognized with national and provincial awards for quality and innovation. Its manufacturing facilities in Nanjing are equipped with advanced testing equipment and comply with regulatory certifications including local GMP and DMF certifications.
Recent major company changes include a strategic move towards capital operations and expansion through acquisitions, notably signing a letter of intent to acquire asset groups from Future Pharmaceutical to enrich its product pipelines and support its "big health" strategy, focusing on an all-age health management product matrix and optimizing product lines in anti-infection, chronic disease, and nutritional support. NanJing Pharmaceutical also advanced its digital transformation by capital increase in its wholly-owned subsidiary Zhongjian Information to enhance competitiveness. In 2025, the company completed a significant equity buyback and obtained approval for a restricted stock incentive plan. Additionally, it plans to issue medium-term notes up to 5 billion yuan to optimize debt structure and broaden financing channels. It has expanded its operations through leasing factory buildings in Nanjing for warehousing and office use to support business growth.
Founded in 1958 and headquartered in Nanjing, Jiangsu Province, China, NanJing Pharmaceutical serves both domestic and international markets, targeting healthcare providers, pharmaceutical distributors, and government health sectors. It maintains a nationwide marketing network and focuses on innovation in drug research and clinical development, including advancing Phase III trials for new drug candidates to enhance its product pipeline and commercial offerings. The company is publicly listed on the Shanghai Stock Exchange under the ticker 600713.SS.